HALO News and Press, Halozyme Therapeutics Inc. From 09/13/19

SAN DIEGO , Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its ...

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with this Read more ...

SAN DIEGO , Aug. 26, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Wells Fargo Healthcare Conference in Boston, MA.  Dr. Helen Torley , president and...

Halozyme Therapeutics, Inc. (HALO) Q2 2019 Earnings Conference Call August 6, 2019 16:30 ET Company Participants Albert Kildani - VP, IR & Corporate Communications Helen Torley - President, CEO & Director Laurie Stelzer - SVP & CFO Alison Armour - SVP, R&D Co...

Halozyme Therapeutics (NASDAQ: HALO ): Q2 GAAP EPS of -$0.10 beats by $0.05 . More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Aug. 6, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the second quarter ended June 30, 2019 and provided an update on recent corporate a...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

SAN DIEGO , July 25, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 39th Annual Canaccord Genuity Growth Conference in Boston, MA.  Laurie Stelzer, senior v...

SAN DIEGO , July 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the second quarter 2019 on Tuesday, August 6 at 4:30 p.m. ET ...